Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (XETRA: VX1) is trading at €464.75, about ₹50,795 at today's EUR/INR rate, as of 29 Sep 2026, 3:04 AM ET, up 0.04% today. Indian residents can buy Vertex Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
€464.75
Today's high
€464.75
52 week low
€330.45
52 week high
€480.40
VX1 opened at €464.75, closed previously at €464.55, and has traded between €330.45 and €480.40 over the past 52 weeks.
About
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily engaged in the development and commercialization of groundbreaking treatments for cystic fibrosis. Its existing portfolio includes therapies such as SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, prescribed for individuals with cystic fibrosis who exhibit particular mutations in their cystic fibrosis transmembrane conductance regulator gene. Additionally, TRIKAFTA is available for CF patients aged six and older possessing at least one F508del mutation. Beyond CF, Vertex maintains a robust development pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin deficiency; VX-147, also in Phase 2, targeting APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other significant renal conditions; VX-880, a Type 1 Diabetes treatment undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor for acute, neuropathic, and musculoskeletal pain, in Phase 2; and CTX001, a Phase 3 candidate for severe sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT). The company distributes its products through specialty pharmacies and distributors within the United States, and globally via specialty distributors, retail chains, hospitals, and clinics. Vertex actively collaborates with numerous entities including Affinia Therapeutics, Inc., Arbor Biotechnologies, Inc., CRISPR Therapeutics AG., Kymera Therapeutics, Inc., Mammoth Biosciences, Inc., Moderna, Inc., Obsidian Therapeutics, Inc., Skyhawk Therapeutics, Inc., Ribometrix, Inc., Genomics plc, Merck KGaA, Darmstadt, Germany, and X-Chem, Inc. Founded in 1989, Vertex Pharmaceuticals Incorporated is headquartered in Boston, Massachusetts.
Key statistics
Avg. volume
76.00
Market cap
€117.96B
P/E Ratio
30.47
Price-to-sales ratio
10.61
Enterprise value
$129.76B
Free cash flow yield
2.83%
Debt-to-equity ratio
0.10
Return on equity
23.31%
ROIC
17.33%
Beta
0.14
Dividend yield
0.00%
Last dividend
€0.00
Financial overview
Revenue
$12.08B
Earnings per share
$15.46
Free cash flow
$3.19B
Net profit margin
34.89%
Gross margin
86.04%
EBITDA
$4.97B
Revenue growth
9.58%
How to buy Vertex Pharmaceuticals from India
Indian residents can buy Vertex Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to EUR.
Search for Vertex Pharmaceuticals and place an order
Find Vertex Pharmaceuticals by name or by its ticker, VX1, and choose an order type. Vertex Pharmaceuticals trades 12:30 pm – 9:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Vertex Pharmaceuticals position in EUR and INR. Vertex Pharmaceuticals pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Vertex Pharmaceuticals from India
Trading and taxes when buying Vertex Pharmaceuticals from India
Trading and limits
- Trading hours
- 9:00 am – 5:30 pm CET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneVertex Pharmaceuticals does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Vertex Pharmaceuticals stock?
Yes. Vertex Pharmaceuticals (VX1) has been listed on XETRA since 2007, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to EUR. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Vertex Pharmaceuticals share cost in rupees?
One Vertex Pharmaceuticals share is €464.75 — about ₹50,795 at an EUR/INR rate of 109.29 on 28 Sep 2026. Both the Vertex Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Vertex Pharmaceuticals from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on Vertex Pharmaceuticals shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the EUR/INR rate on the purchase and the sale date, so the rupee move counts alongside the Vertex Pharmaceuticals price. Paasa issues a capital-gains statement for your return.
Does Vertex Pharmaceuticals pay a dividend?
No. Vertex Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Vertex Pharmaceuticals from India?
XETRA trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when Germany is on standard time. Orders can only execute during that window.
Is Vertex Pharmaceuticals a Germany company, and does that change how it is taxed?
Vertex Pharmaceuticals trades on XETRA in EUR, but the company is domiciled in United States. Vertex Pharmaceuticals trades as an ordinary share listed directly in Germany, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Vertex Pharmaceuticals shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Vertex Pharmaceuticals holding, its cost and its closing value.
How do I sell Vertex Pharmaceuticals and bring the money back to India?
You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in EUR in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.
Does the rupee rate affect what I make on Vertex Pharmaceuticals?
Yes. Vertex Pharmaceuticals is priced in EUR, so your rupee outcome combines the EUR move with the EUR/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.